Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal a…
Source:Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers
Tuesday, December 16, 2014
Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment